NCT03047980View on ClinicalTrials.gov

Trial of Sirolimus for Cognitive Impairment in Sturge-Weber Syndrome

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

January 31, 2017

Primary Completion Date

June 4, 2019

Study Completion Date

October 27, 2020

Conditions
Sturge-Weber Syndrome
Interventions
DRUG

Sirolimus

Low dose oral sirolimus

Trial Locations (2)

21205

Kennedy Krieger Institute, Baltimore

45229

Cincinnati Children's Hospital Medical Center, Cincinnati

Sponsors

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Children's Hospital Medical Center, Cincinnati

OTHER

collaborator

Pfizer

INDUSTRY

collaborator

National Institutes of Health (NIH)

NIH

collaborator

Faneca 66 Foundation

OTHER

collaborator

National Institute of Neurological Disorders and Stroke (NINDS)

NIH

lead

Anne Comi, MD

OTHER

NCT03047980 - Trial of Sirolimus for Cognitive Impairment in Sturge-Weber Syndrome | Biotech Hunter | Biotech Hunter